Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333166 | 0.86 | RET (0.44) | RETKCNH2TLK2 | |
| SCHEMBL6778312 | 0.85 | RET (0.45) | RETTLK2 | |
| SCHEMBL6335636 | 0.84 | RET (0.40) | RETTLK2 | |
| SCHEMBL6338486 | 0.83 | RET (0.43) | RETTLK2 | |
| SCHEMBL6337237 | 0.82 | RET (0.43) | MEN1KMT2ARETTLK2 | |
| SCHEMBL6329680 | 0.82 | RET (0.49) | MEN1KMT2AKDM4EALDH1A1RET | |
| SCHEMBL6337189 | 0.82 | RET (0.44) | RETTLK2 | |
| SCHEMBL6329102 | 0.82 | RET (0.45) | RETTLK2 | |
| SCHEMBL6329200 | 0.82 | ACHE (0.45) | RET | |
| SCHEMBL6336940 | 0.82 | ACHE (0.45) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | MEN1 1645/4885KMT2A 1678/4885KDM4E 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.